Check out the new and improved FierceBiotech.com

Arsalan Arif, Publisher
Follow me on Twitter and LinkedIn

Dear readers: We've completed a major overhaul of FierceBiotech's website.

We had one guiding principle with the redesign. It's best captured by Jay Rosen, a prominent press critic and journalism professor at NYU:

"The simplest way to create value in journalism is to save the user time."

Please explore the streamlined new design and let us know if we indeed are saving you time. You, our readers, are some of the busiest executives in the world, so our mission is to give you great content and context in the daily biotechnology news picture as expeditiously as possible. Drop me a line, tell us how we're doing in that regard. After all, we built it for you.

 

Suggested Articles

The inclusion of Kupffer cells in in vitro hepatic cultures provides researchers with advanced tools for disease modeling and drug discovery.

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.